Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Cancer Survival Analysis01:21

Cancer Survival Analysis

407
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
407
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

5.2K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.2K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

279
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
279

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Synthesis, In Vitro Anticancer Activity, Molecular Docking, and Dynamic Simulation Study of Thiazole-Conjugated Pyrazole Derivatives.

Chemistry & biodiversity·2025
Same author

Pyrazole Scaffold: Potential PTP1B Inhibitors for Diabetes Treatment.

Current diabetes reviews·2024
Same author

Biocompatibility assessment of chemically modified GONRs with hemoglobin and histopathological studies for its toxicity evaluation.

Dalton transactions (Cambridge, England : 2003)·2023
Same author

Development and Characterization of Pentaerythritol-EudragitRS100 Co-processed Excipients as Solid Dispersion Carriers for Enhanced Aqueous Solubility, <i>In Vitro</i> Dissolution, and <i>Ex Vivo</i> Permeation of Atorvastatin.

ACS omega·2023
Same author

New Benzopyrrole Derivatives: Synthesis and Appraisal of Their Potential as Antimicrobial Agents.

Chemistry & biodiversity·2023
Same author

Preparation of Terbinafin-Encapsulated Solid Lipid Nanoparticles Containing Antifungal Carbopol<sup>®</sup> Hydrogel with Improved Efficacy: In Vitro, Ex Vivo and In Vivo Study.

Pharmaceutics·2022

Related Experiment Video

Updated: Aug 6, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

465

A Review of Research from 2012 to 2024 on Pyrazole-based Anticancer Agents with SAR Study.

Deepali Wanode1, Deweshri Nandurkar2, Megha Ambatkar1

  • 1Department of Pharmaceutical Sciences, Rashtrasant Tukadoji Maharaj Nagpur University, Nagpur 440033, India.

Current Topics in Medicinal Chemistry
|June 13, 2025
PubMed
Summary
This summary is machine-generated.

Pyrazole derivatives show significant promise as anticancer agents. This review covers research from 2012-2024, highlighting FDA-approved and clinical trial pyrazole-based chemotherapeutics.

Keywords:
CancerFDA approved pyrazole derivativesanticancerdrugs under clinical trial.hybridspyrazole

More Related Videos

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
05:17

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

1.5K
Microwave-Assisted Preparation of 1-Aryl-1H-pyrazole-5-amines
05:07

Microwave-Assisted Preparation of 1-Aryl-1H-pyrazole-5-amines

Published on: June 23, 2019

6.6K

Related Experiment Videos

Last Updated: Aug 6, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

465
Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
05:17

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

1.5K
Microwave-Assisted Preparation of 1-Aryl-1H-pyrazole-5-amines
05:07

Microwave-Assisted Preparation of 1-Aryl-1H-pyrazole-5-amines

Published on: June 23, 2019

6.6K

Area of Science:

  • Oncology
  • Medicinal Chemistry

Background:

  • Pyrazole derivatives are increasingly investigated for their anticancer properties.
  • The development of novel chemotherapeutic agents is crucial for cancer treatment.
  • Existing pyrazole-based drugs and those in clinical trials demonstrate therapeutic potential.

Purpose of the Study:

  • To provide a comprehensive review of pyrazole derivatives as anticancer agents.
  • To analyze research trends in this field from 2012 to 2024.
  • To guide future research and development of pyrazole-based cancer therapeutics.

Main Methods:

  • Literature review of scientific publications and clinical trial data.
  • Analysis of synthetic pyrazole derivatives with reported anticancer activity.
  • Focus on compounds approved by the Food and Drug Administration (FDA) and those in clinical trials.

Main Results:

  • Identification of numerous pyrazole derivatives with significant anticancer activity.
  • Documentation of FDA-approved pyrazole-based chemotherapeutics.
  • Summary of pyrazole derivatives currently undergoing clinical trials for cancer treatment.

Conclusions:

  • Pyrazole derivatives represent a vital class of compounds in cancer research.
  • Continued investigation into pyrazole derivatives is essential for developing next-generation cancer therapies.
  • This review serves as a foundation for future innovation in pyrazole-based oncology.